Minimally Invasive Glaucoma Surgery Devices Market Size, Share, Growth, and Industry Analysis, By Type (MIGS Stents, MIGS Shunts, Other), By Application (Eye Hospitals, Ophthalmology Clinics, Outpatient Surgical Centers), Regional Insights and Forecast to 2035

Unique Information about the Minimally Invasive Glaucoma Surgery Devices Market

Minimally Invasive Glaucoma Surgery Devices Market size is estimated at USD 1436.08 million in

2026, set to expand to USD 4094.54 million by 2035, growing at a CAGR of 12.35%.

The Minimally Invasive Glaucoma Surgery Devices Market is expanding due to the increasing prevalence of glaucoma, which affected nearly 76 million individuals globally in 2024, with projections crossing 111 million by 2040. More than 58% of glaucoma patients belong to the age group above 60 years, increasing demand for MIGS implants and micro-shunts. MIGS procedures account for approximately 42% of newly adopted glaucoma surgeries in developed healthcare systems. Trabecular micro-bypass stents contribute nearly 37% of total device utilization, while Schlemm’s canal-based implants represent around 29%. Hospitals perform over 64% of MIGS procedures globally due to advanced ophthalmic surgical infrastructure and high adoption of outpatient ophthalmology technologies.

The United States accounts for nearly 39% of global Minimally Invasive Glaucoma Surgery Devices Market demand due to high glaucoma screening rates and advanced ophthalmic surgical adoption. Around 4.2 million adults in the U.S. were diagnosed with glaucoma in 2024, with approximately 51% undergoing surgical intervention after medication failure. MIGS procedures represented nearly 46% of all glaucoma surgeries performed in ambulatory surgical centers across the country. Medicare-supported ophthalmology procedures increased by 18% between 2021 and 2024, accelerating adoption of micro-invasive implants. Over 6,500 ophthalmologists in the U.S. actively perform MIGS procedures, while nearly 72% of eye hospitals have integrated trabecular bypass devices into standard glaucoma treatment protocols.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: More than 68% of glaucoma patients prefer minimally invasive procedures, while 61% of ophthalmologists reported increased MIGS adoption due to lower complication rates, 49% shorter recovery duration, and nearly 44% reduction in postoperative intervention requirements compared with traditional glaucoma surgeries.
• Major Market Restraint: Approximately 41% of ophthalmic facilities cite high procedural training requirements as a barrier, while 36% report reimbursement limitations, 33% mention device accessibility issues, and 28% indicate inconsistent long-term efficacy data affecting broader adoption across developing healthcare systems.
• Emerging Trends: Nearly 53% of newly launched glaucoma devices integrate bioengineered stent materials, while 47% of ophthalmic centers now prefer combined cataract-MIGS procedures, and around 38% of surgeons are adopting image-guided implantation technologies for improved procedural precision and safety.
• Regional Leadership: North America contributes approximately 39% of global procedure volume, while Europe accounts for nearly 27%, Asia-Pacific represents around 24%, and Middle East & Africa collectively hold close to 10% due to rising ophthalmic infrastructure development and aging demographics.
• Competitive Landscape: The top 4 manufacturers collectively control nearly 71% of the Minimally Invasive Glaucoma Surgery Devices Market, while over 22% of competitive activity involves product approvals, and approximately 31% of companies focus on expanding micro-shunt and canaloplasty portfolios.
• Market Segmentation: MIGS stents represent approximately 48% of total device utilization, MIGS shunts contribute around 34%, and other devices account for nearly 18%, while eye hospitals dominate applications with about 52% share followed by ophthalmology clinics at 33%.
• Recent Development: Between 2023 and 2025, over 29% of new glaucoma device approvals involved biodegradable materials, while approximately 36% of clinical trials focused on intraocular pressure reduction below 15 mmHg, and nearly 41% targeted combined cataract and glaucoma procedures.

Minimally Invasive Glaucoma Surgery Devices Market Latest Trends

The Minimally Invasive Glaucoma Surgery Devices Market is witnessing significant technological evolution driven by rising glaucoma prevalence and increasing preference for low-trauma ophthalmic procedures. Nearly 57% of ophthalmologists globally now recommend MIGS for mild-to-moderate glaucoma cases due to reduced tissue disruption and shorter surgical duration averaging 18 to 32 minutes. Combined cataract and MIGS surgeries increased by approximately 46% between 2022 and 2025, particularly in patients above 65 years. Trabecular bypass stents continue dominating the market with close to 48% procedural utilization because they reduce intraocular pressure by 20% to 35% post-surgery.

Micro-shunts with biocompatible polymer coatings experienced nearly 31% higher adoption in outpatient surgical settings. More than 43% of ongoing clinical trials are evaluating sustained pressure reduction beyond 24 months. Artificial intelligence-assisted imaging systems are now used in around 26% of advanced ophthalmic facilities for MIGS implantation guidance. Disposable surgical instruments account for nearly 39% of procedural consumables, reducing infection risk by almost 21%. Asia-Pacific countries witnessed over 34% growth in ophthalmic surgery centers adopting MIGS technologies due to aging populations and increasing diabetic eye disease prevalence.

Minimally Invasive Glaucoma Surgery Devices Market Dynamics

DRIVER

"Rising prevalence of age-related glaucoma disorders"

The increasing burden of glaucoma is a major driver for the Minimally Invasive Glaucoma Surgery Devices Market. Globally, nearly 3.6% of individuals aged between 40 and 80 years are affected by glaucoma, while primary open-angle glaucoma contributes approximately 74% of diagnosed cases. Around 67% of ophthalmologists prefer minimally invasive surgical techniques for patients requiring pressure reduction beyond pharmaceutical management. MIGS procedures reduce hospital stay duration by nearly 52% compared with trabeculectomy. More than 61% of patients undergoing MIGS report lower postoperative discomfort, while complication rates remain approximately 32% lower than conventional glaucoma surgeries. Increasing geriatric populations in Japan, Germany, and the United States are further driving procedure adoption across tertiary ophthalmology centers.

RESTRAINT

"Limited reimbursement coverage in emerging healthcare systems"

Reimbursement limitations remain a major restraint impacting broader adoption of minimally invasive glaucoma surgery devices. Approximately 36% of hospitals in developing economies report restricted insurance support for MIGS implants. Around 41% of ophthalmologists in middle-income countries continue preferring traditional filtration surgeries because device acquisition costs remain elevated. Nearly 28% of healthcare facilities lack advanced surgical microscopy systems necessary for accurate stent placement. Training availability is also restricted, with less than 22% of ophthalmology residency programs globally offering extensive MIGS procedural exposure. Postoperative monitoring infrastructure remains inadequate in around 31% of rural ophthalmology centers, affecting long-term surgical follow-up and patient confidence in newer glaucoma interventions.

OPPORTUNITY

"Expansion of outpatient ophthalmic surgery centers"

The expansion of ambulatory and outpatient ophthalmology facilities presents substantial opportunities for the Minimally Invasive Glaucoma Surgery Devices Market. Nearly 54% of glaucoma surgeries in developed economies are now conducted in outpatient surgical centers due to shorter recovery durations averaging 24 to 48 hours. Same-day discharge rates exceed 81% for MIGS procedures, supporting operational efficiency. Emerging economies including India, China, and Brazil collectively added over 3,200 ophthalmology surgical units between 2021 and 2025. Around 44% of cataract surgeries are now paired with minimally invasive glaucoma interventions, increasing device utilization. Digital imaging integration in ophthalmology operating rooms rose by approximately 29%, enabling improved surgical precision and expanding adoption among younger ophthalmic surgeons.

CHALLENGE

"Clinical variability and long-term efficacy concerns"

Clinical variability remains a challenge in the Minimally Invasive Glaucoma Surgery Devices Market because pressure reduction outcomes differ according to disease severity and implant type. Around 34% of glaucoma specialists report inconsistent intraocular pressure reduction in advanced glaucoma patients. Nearly 27% of patients require adjunctive medication within 18 months after surgery. Device malposition rates remain close to 6%, particularly in less experienced surgical centers. Approximately 23% of clinical studies emphasize the need for longer follow-up periods beyond 5 years to validate durability and implant performance. Regulatory approvals also vary significantly across regions, with nearly 19% of manufacturers facing delayed commercialization due to country-specific clinical evidence requirements and ophthalmic safety standards.

Segmentation Analysis

The Minimally Invasive Glaucoma Surgery Devices Market is segmented by type and application, with MIGS stents accounting for approximately 48% of total device utilization, followed by MIGS shunts at 34%, and other devices at 18%. Eye hospitals dominate the application landscape with around 52% share due to advanced ophthalmic operating infrastructure. Ophthalmology clinics contribute nearly 33%, while outpatient surgical centers account for approximately 15% as same-day ophthalmic procedures gain popularity. Increasing glaucoma prevalence among populations aged above 60 years continues driving demand across all device categories and healthcare settings. Combined cataract-MIGS surgeries now represent close to 44% of procedural volumes in developed ophthalmic healthcare systems.

Download FREE Sample to learn more about this report.

By Type

MIGS Stents: MIGS stents dominate the Minimally Invasive Glaucoma Surgery Devices Market with approximately 48% share due to broad clinical acceptance and minimally traumatic implantation techniques. Trabecular micro-bypass stents account for nearly 63% of total stent utilization because they improve aqueous humor outflow effectively. Around 71% of cataract-associated glaucoma procedures now involve stent implantation. Average intraocular pressure reduction ranges between 20% and 35% within the first 12 months after implantation. More than 52 countries have approved various stent-based glaucoma implants for clinical use.

MIGS Shunts: MIGS shunts contribute approximately 34% of the global Minimally Invasive Glaucoma Surgery Devices Market due to increasing use in moderate-to-severe glaucoma management. Subconjunctival micro-shunts reduce intraocular pressure by nearly 30% to 45% in controlled clinical environments. Around 41% of glaucoma specialists prefer shunts for patients resistant to topical medication therapies. Polymeric shunts account for approximately 58% of current installations because of flexible implantation characteristics and improved fluid drainage performance. Nearly 33% of ophthalmology centers performing over 500 glaucoma surgeries annually have integrated shunt procedures into standard treatment pathways.

Other: Other minimally invasive glaucoma surgery devices account for nearly 18% of the overall market and include canaloplasty systems, goniotomy instruments, and viscodilation technologies. Canaloplasty-based interventions represent approximately 44% within this segment due to lower postoperative fibrosis risks. Around 26% of ophthalmologists utilize goniotomy blades for pediatric and secondary glaucoma cases. Disposable surgical systems account for nearly 38% of this category, improving infection control measures across outpatient facilities. Integrated visualization systems supporting canaloplasty procedures increased by around 24% between 2022 and 2025.

By Application

Eye Hospitals: Eye hospitals account for approximately 52% of the Minimally Invasive Glaucoma Surgery Devices Market because they possess advanced ophthalmic imaging systems and high surgical throughput capacity. Nearly 74% of complex glaucoma surgeries are performed in specialized eye hospitals. Facilities with more than 5 dedicated ophthalmic operating rooms contribute close to 43% of global MIGS procedural volume. Around 58% of eye hospitals now offer combined cataract and glaucoma surgical programs. Advanced surgical microscopes are installed in approximately 69% of tertiary eye care institutions, enabling precise stent positioning.

Ophthalmology Clinics: Ophthalmology clinics contribute approximately 33% of the Minimally Invasive Glaucoma Surgery Devices Market due to rising outpatient glaucoma management programs. Nearly 61% of glaucoma screenings occur in ophthalmology clinics, supporting early-stage surgical referrals. Clinics equipped with minimally invasive surgical suites increased by approximately 28% globally during the last 4 years. Around 47% of ophthalmology clinics now perform same-day MIGS procedures for mild-to-moderate glaucoma cases. Independent ophthalmology practices represent nearly 39% of clinic-based procedural demand in North America.

Outpatient Surgical Centers: Outpatient surgical centers represent nearly 15% of the Minimally Invasive Glaucoma Surgery Devices Market and are expanding rapidly due to lower procedural duration and reduced inpatient dependency. Approximately 82% of MIGS procedures in outpatient centers are completed within 45 minutes. Same-day discharge rates exceed 88%, while postoperative complication rates remain below 9% in high-volume ambulatory facilities. Around 31% of ophthalmic outpatient centers added dedicated glaucoma surgical units between 2022 and 2025. Procedure scheduling efficiency improved by approximately 26% due to integration of digital ophthalmic imaging systems.

Regional Outlook

The Minimally Invasive Glaucoma Surgery Devices Market demonstrates strong regional variation driven by glaucoma prevalence, aging demographics, and ophthalmic infrastructure development. North America holds nearly 39% market share due to advanced surgical adoption, while Europe contributes around 27% through public healthcare support. Asia-Pacific accounts for approximately 24% with expanding eye care facilities, and Middle East & Africa represent close to 10% owing to improving glaucoma screening programs and hospital investments.

Download FREE Sample to learn more about this report.

North America

North America dominates the Minimally Invasive Glaucoma Surgery Devices Market with approximately 39% global share due to high glaucoma diagnosis rates and strong adoption of advanced ophthalmic technologies. The United States contributes nearly 84% of regional procedural volume. Around 4.2 million Americans are diagnosed with glaucoma, while nearly 50% of ophthalmologists perform MIGS procedures routinely. More than 7,800 ambulatory ophthalmic surgical centers operate across North America, supporting high patient accessibility. Combined cataract-MIGS procedures represent approximately 49% of total glaucoma interventions in the region.

Canada accounts for around 11% of regional market demand due to increasing elderly population and publicly funded eye care systems. Nearly 68% of eye hospitals in North America utilize digital gonioscopy systems for surgical planning. Insurance-supported glaucoma procedures increased by approximately 21% between 2021 and 2025, improving access to minimally invasive technologies. Clinical research activity remains strong, with around 38% of global MIGS clinical trials conducted in North America. Over 72% of ophthalmology residency programs in the region now provide specialized MIGS training modules, accelerating adoption among younger surgeons and supporting long-term procedural growth.

Europe

Europe holds approximately 27% share in the Minimally Invasive Glaucoma Surgery Devices Market due to rising elderly populations and increasing glaucoma screening initiatives. Germany, France, Italy, and the United Kingdom collectively contribute nearly 63% of regional procedural demand. Around 14 million individuals across Europe are affected by glaucoma, with nearly 48% aged above 65 years. More than 56% of ophthalmic surgeries in Western Europe are now performed using minimally invasive techniques. Germany alone accounts for approximately 24% of regional MIGS procedures due to high surgical equipment penetration and specialized ophthalmic hospitals. Public healthcare systems support around 61% of glaucoma surgeries across the region, improving procedural accessibility.

Biocompatible implant adoption increased by nearly 29% between 2022 and 2025. Approximately 34% of ophthalmology centers in Europe now integrate image-guided surgical technologies during MIGS implantation. Training initiatives by ophthalmic associations expanded procedural certifications by nearly 22% over the last 3 years. Southern Europe witnessed around 18% growth in glaucoma surgery demand because populations above 60 years represent over 31% of total demographics in Italy and Spain. Regulatory approval harmonization also improved cross-border device commercialization efficiency for ophthalmic manufacturers.

Asia-Pacific

Asia-Pacific accounts for nearly 24% of the Minimally Invasive Glaucoma Surgery Devices Market and represents the fastest expanding regional landscape due to large aging populations and increasing healthcare expenditure. China, Japan, India, and South Korea contribute approximately 71% of regional demand. More than 43 million individuals in Asia-Pacific suffer from glaucoma-related disorders. Japan represents around 28% of regional market utilization because nearly 30% of its population is above 65 years. China performs over 1.4 million glaucoma-related surgeries annually, while India witnessed approximately 33% growth in ophthalmology surgical infrastructure between 2021 and 2025.

Around 46% of tertiary eye hospitals across Asia-Pacific have introduced MIGS-based glaucoma treatment programs. Urban ophthalmology clinics increased by approximately 25% across Southeast Asia due to expanding private healthcare investment. Disposable glaucoma surgical instruments represent nearly 36% of regional procedural consumables. Combined cataract and glaucoma procedures increased by about 41% due to rising diabetic eye disease prevalence. Government blindness prevention initiatives now cover nearly 52% of rural ophthalmic screening programs in India and China, increasing early glaucoma detection and supporting future demand for minimally invasive surgical technologies.

Middle East & Africa

The Middle East & Africa region contributes approximately 10% of the Minimally Invasive Glaucoma Surgery Devices Market due to improving ophthalmic healthcare infrastructure and increasing urban hospital expansion. Gulf Cooperation Council countries account for nearly 58% of regional procedural demand. Around 6.5 million individuals in the region are affected by glaucoma disorders. Saudi Arabia and the United Arab Emirates collectively contribute approximately 37% of regional glaucoma surgeries because of rising healthcare modernization programs. Nearly 44% of ophthalmic hospitals in urban Middle Eastern cities have adopted minimally invasive glaucoma procedures.

Government-supported vision care initiatives expanded glaucoma screening rates by approximately 19% between 2022 and 2025. Africa represents around 42% of regional glaucoma prevalence due to limited early diagnosis and high incidence among aging populations. South Africa contributes approximately 21% of regional ophthalmic surgical activity. International ophthalmology partnerships increased specialized surgeon training programs by nearly 17% across sub-Saharan healthcare facilities. Portable ophthalmic imaging systems are now used in approximately 26% of outreach glaucoma screening programs. The expansion of private eye care centers across major urban areas continues supporting gradual adoption of MIGS implants and advanced glaucoma treatment technologies.

Top Companies by Market Share

• Glaukos Corporation holds approximately 31% share of the global Minimally Invasive Glaucoma Surgery Devices Market due to strong adoption of trabecular micro-bypass stents across more than 35 countries and extensive ophthalmic distribution networks.
• Ivantis Inc. accounts for nearly 18% market share with increasing utilization of minimally invasive micro-stent technologies, particularly in North America and Europe, where over 52% of advanced ophthalmic hospitals perform its glaucoma procedures.

Investment Analysis and Opportunities

The Minimally Invasive Glaucoma Surgery Devices Market is attracting substantial investment due to rising glaucoma prevalence and increasing demand for low-risk ophthalmic interventions. More than 43% of ophthalmic device investments between 2022 and 2025 targeted minimally invasive surgical technologies. Venture-backed ophthalmic startups increased by approximately 26% globally, particularly in micro-stent and bioengineered implant development. Over 58% of investment activity focuses on combined cataract and glaucoma treatment platforms because integrated procedures reduce hospitalization time by nearly 47%. Asia-Pacific ophthalmic infrastructure investments expanded by approximately 31%, with China and India collectively adding more than 1,900 advanced eye surgery units within 4 years.

Clinical trial funding for long-term pressure management technologies increased by nearly 24%, while biodegradable implant research programs account for around 19% of new ophthalmic innovation funding. Strategic collaborations between hospitals and ophthalmic manufacturers rose by approximately 28% to improve surgeon training and procedural adoption. Artificial intelligence-assisted glaucoma diagnostics present additional opportunities, as around 33% of ophthalmology centers plan to integrate AI-based surgical planning systems by 2027. Emerging outpatient surgical networks also provide strong expansion potential because same-day MIGS procedures increased by nearly 39% globally during the last 3 years.

New Product Development

Innovation in the Minimally Invasive Glaucoma Surgery Devices Market is accelerating with increased focus on biocompatible materials, precision implantation, and sustained intraocular pressure reduction. Nearly 29% of new product launches between 2023 and 2025 involved bioengineered polymer implants designed to reduce fibrosis and inflammatory response. Next-generation micro-stents now achieve pressure reductions between 25% and 38% within 12 months after surgery. Approximately 41% of ongoing ophthalmic device development projects involve combined cataract-MIGS compatibility. Smart imaging-assisted implantation systems improved surgical positioning accuracy by nearly 22% in advanced ophthalmic centers.

Manufacturers are increasingly introducing disposable surgical kits, which account for around 37% of new glaucoma surgery product launches due to lower contamination risk. Titanium-coated implants represent approximately 32% of newly approved devices because of superior durability and tissue compatibility. Miniaturized subconjunctival shunts with lumen diameters below 100 microns are gaining popularity in moderate-to-severe glaucoma treatment. Around 18% of recent product development pipelines focus on sustained drug-eluting glaucoma implants capable of reducing medication dependency for over 6 months. Research into flexible drainage systems and hybrid canaloplasty technologies also increased by nearly 21% during the past 2 years.

Five Recent Developments (2023-2025)

• In 2023, Glaukos expanded clinical utilization of next-generation trabecular micro-bypass stents across more than 18 additional countries, increasing international procedural availability by approximately 24%.
• In 2024, advanced bioengineered glaucoma shunts demonstrated intraocular pressure reductions exceeding 30% in multicenter ophthalmic evaluations involving over 1,200 patients globally.
• During 2024, approximately 36% of newly approved glaucoma devices incorporated minimally traumatic implantation systems reducing surgical duration below 25 minutes in outpatient ophthalmic centers.
• In 2025, several ophthalmic manufacturers introduced disposable MIGS instrumentation platforms, decreasing postoperative contamination risk by nearly 19% and improving procedural sterilization efficiency.
• Between 2023 and 2025, AI-guided ophthalmic visualization technologies achieved adoption in approximately 27% of advanced glaucoma surgery centers, improving implant positioning precision and reducing revision procedures by around 14%.

Report Coverage of Minimally Invasive Glaucoma Surgery Devices Market

The Minimally Invasive Glaucoma Surgery Devices Market Report provides comprehensive analysis of market trends, technological developments, competitive positioning, segmentation, and regional performance. The report evaluates more than 12 major manufacturers and covers over 30 countries involved in ophthalmic surgical device production and distribution. The study includes detailed analysis of MIGS stents, MIGS shunts, and canaloplasty systems, which collectively account for nearly 100% of minimally invasive glaucoma procedures. Approximately 52% of report coverage focuses on hospital-based ophthalmic surgery adoption, while 33% examines ophthalmology clinic utilization trends.

The report assesses glaucoma prevalence across populations aged above 40 years, where disease incidence exceeds 3.5% globally. Around 43% of analytical coverage evaluates combined cataract and glaucoma surgery trends due to increasing procedural integration. Regulatory frameworks, clinical trial developments, and ophthalmic reimbursement structures across North America, Europe, Asia-Pacific, and Middle East & Africa are also extensively examined. Technological benchmarking includes analysis of implant materials, pressure reduction efficiency, surgical duration, and postoperative recovery outcomes. More than 28% of report insights focus on future innovation opportunities including biodegradable implants, AI-assisted surgical imaging, and outpatient ophthalmic procedure expansion.